“Following Cybin’s recent acquisition of Small Pharma Inc., our development programs are protected by 32 granted patents and over 170 pending applications…”
From Doug Drysdale, Cybin’s Chief Executive Officer. Well, today Cybin has added to this growing IP portfolio with the granting of two more patents for its DMT program. The new United States patent grants offer protection for deuterated analogs of DMT including composition of matter, medical use and synthesis.
For more on Cybin’s patents, check out Cybin Granted U.S. Patent For Psilocybin Program and Cybin Granted U.S. Patent for 5-MeO-DMT
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
October 25, 2023
– New United States patent grants offer protection for deuterated analogs of DMT including composition of matter, medical use and synthesis –
– Intellectual Property portfolio provides robust protection for most extensive deuterated DMT portfolio in the sector –
– Cybin’s Intellectual Property portfolio now consists of 32 granted patents and over 170 pending applications –
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the United States Patent and Trademark Office has issued two patent grants that offer protection for its deuterated N, N-dimethyltryptamine (“DMT”) program.
The granted patents protecting the Company’s deuterated DMT program are:
- United States patent no. 11,771,681, which provides composition of matter protection for certain deuterated analogs of DMT; and
- United States patent no. 11,773,062, which provides protection for the medical use and the novel, efficient and scalable synthesis of certain analogs of DMT.
Cybin’s proprietary novel deuterated DMT compounds, CYB004 and SPL028, are each currently in Phase I clinical trials. CYB004 and SPL028 target an extended DMT psychedelic experience while retaining a short-duration drug profile that could provide optimized dose formulations for different administration routes and distinct therapeutic benefits for patients. Preliminary findings from the studies demonstrate that IV CYB004 and SPL028 elicit a psychedelic experience of less than 1 hour and are well-tolerated. Topline data readouts from both studies are expected in Q4 2023.
“Following Cybin’s recent acquisition of Small Pharma Inc., our development programs are protected by 32 granted patents and over 170 pending applications, establishing our leadership position in developing novel tryptamine-based therapeutics in a key market. This multi-layered and robust IP protection includes composition of matter, medical use, synthesis and drug product protection, providing us with the latitude to advance our deuterated programs with confidence,” said Doug Drysdale, Cybin’s Chief Executive Officer.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
psilocybin dmt n-dimethyltryptamine dimethyltryptamine psychedelic therapeutics analog major depressive disorder depressive disorder anxiety cybin small pharma synthesis research